Pfizer To Buy Biohaven Pharmaceuticals In $11.6B Deal
Pfizer Inc., advised by Ropes & Gray LLP, plans to buy Sullivan & Cromwell LLP-led Biohaven Pharmaceuticals, a drugmaker known for developing migraine treatment, for about $11.6 billion, the companies said...To view the full article, register now.
Already a subscriber? Click here to view full article